Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Apr 2023
Adding mint flavor to e-cigarette liquids increases the amount of vapour particles produced and is linked, according to a recent study published in Respiratory Research.
Read Full NewsIn a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?
New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.
A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.
A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.
1.
Urinary tract cancer prediction models with high sensitivity and specificity
2.
AI tool automates liver tumor detection and monitoring
3.
Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain
4.
Knowing about and avoiding bladder cancer.
5.
AI is equally capable of reading breast cancer scans as human radiologists.
1.
Decoding the Future: Cancer Genomics and Radiomics in Oncology
2.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
3.
Clinical Analysis of Prostate Cancer
4.
Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options
5.
Unlocking the Mystery of Ovarian Cancer Staging
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
2.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
5.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge